CD19-Directed Antibody-Drug Conjugates for DLBCL

Drawing Comparisons for Relevant Therapies in Patients With DLBCL

Elizabeth A. Brem, MD, discusses treatment options for patients with diffuse large B-cell lymphoma.

Hematologists Should Consider What Comes Next for Patients With DLBCL

Elizabeth A. Brem, MD, discusses the familiarity of treatments among oncologists for patients with diffuse large B-cell lymphoma in a Case-Based Roundtable event.

Community Oncologists Show Comfort With Bispecifics in B-Cell Lymphoma

Elizabeth A. Brem, MD, discusses the shift she has seen in the community setting when it comes to using bispecific antibody therapy for patients with B-cell lymphoma.

Later-Line CD19 and Bispecific Therapies Considered After CAR T

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.

Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed the data behind loncastuximab and whether participants with use this treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.

Loncastuximab Leads to Responses in DLBCL After Prior CD19 CAR T

During a Case-Based Roundtable® event, Amitkumar Mehta, MD, discussed the efficacy of loncastuximab in patients who also received CAR T-cell therapy in the first article of a 2-part series.

Takeaways on Tolerability Challenges With Loncastuximab in DLBCL

During a Case-Based Roundtable® event, Amitkumar Mehta, MD, discussed the study design of the LOTIS-2 trial and adverse events related to loncastuximab tesirine in diffuse large B-cell lymphoma in the first article of a 2-part series.

Different Options Discussed for DLBCL in Later-Lines of Treatment

During a Case-Based Roundtable® event, Matthew Ulrickson, MD, considered treatments for patients with relapsed/refractory diffuse large B-cell lymphoma with event participants in the second article of a 2-part series.

Experience and Sequencing Guide Third-Line DLBCL Therapy Selection

During a Case-Based Roundtable® event, Matthew Ulrickson, MD, discussed experiences with loncastuximab and other targeted treatments in patients with diffuse large B-cell lymphoma with event participants in the first article of a 2-part series.

Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL

During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the long-term results with loncastuximab in patients with diffuse large B-cell lymphoma and how this drug fared in the real-world setting in the second article of a 2-part series.

Fitting Loncastuximab Into the Current Landscape of R/R DLBCL

During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.

Assessing the Durability, Tolerability of Loncastuximab in R/R DLBCL

In the second part of a 2-article series, Matthew Matasar, MD, MS, discusses long-term follow up data from the LOTIS-2 trial and how these data show the durability and tolerability of loncastuximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

ADC Loncastuximab Shows Signs of Durable Response in R/R DLBCL

In the first part of a 2-article series, Matthew Matasar, MD, MS, discusses where loncastuximab fits into the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma and the data that led to the antibody drug conjugate’s approval.

Bispecific Agents Vs Loncastuximab as Third-Line Therapy for R/R DLBCL

During a Targeted Oncology™ Case-Based Roundtable™ event, Paolo Strati, MD, discussed treatment selection and sequencing of loncastuximab in the context of new bispecific T-cell engagers. This is the second of 2 articles based on this event.

Physicians Consider Loncastuximab for Older Patients With R/R DLBCL

During a Targeted Oncology™ Case-Based Roundtable™ event, Paolo Strati, MD, discussed a case of a 73-year-old woman with diffuse large B-cell lymphoma who progressed after second-line therapy.

Bispecific T-Cell Engagers Emerge as Later-Line Therapies for DLBCL

During a Targeted Oncology™ Case-Based Roundtable™ event, Medhi H. Hamadani, MD, discussed the bispecific T-cell engagers epcoritamab and glofitamab and how they fit into the treatment algorithm for patients with diffuse large B-cell lymphoma. This is the second of 2 articles based on this event.

Reviewing Options After CAR T-Cell Therapy Progression in R/R DLBCL

During a Targeted Oncology™ Case-Based Roundtable™ event, Mehdi H. Hamadani, MD, discussed the efficacy of therapies for diffuse large B-cell lymphoma after progression on chimeric antigen receptor T-cell therapy. This is the first of 2 articles based on this event.

Evaluating the Role of Loncastuximab in Relapsed/Refractory DLBCL

During a Targeted Oncology™ Case-Based Roundtable™ event, Brad Haverkos, MD, and other participants discussed the role of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma. This is the second of 2 articles based on this event.

Considerations for Third-Line Therapy for Relapsed/Refractory DLBCL

During a Targeted Oncology™ Case-Based Roundtable™ event, Brad Haverkos, MD, and other participants discussed the choice of treatment options for a patient with relapsed/refractory diffuse large B-cell lymphoma who previously received R-CHOP and pola-BR.

Physicians Discuss Roles of Later-Line Therapies in DLBCL

During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Matasar, MD, MS, discussed with oncologists how they use loncastuximab tesirine and tafasitamab/lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma.

Efficacy Data Support Loncastuximab as Third-Line DLBCL Treatment

During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Matasar, MD, MS, discussed the data supporting the safety and efficacy of loncastuximab tesirine in patients with diffuse large B-cell lymphoma. This is the first of 2 articles based on this event.

Loncastuximab Shows Durable Response in Higher-Risk R/R DLBCL Population

Matthew J. Matasar, MD, discusses the LOTIS-2 trial of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

Loncastuximab Shows Favorable Tolerability in Relapsed/Refractory DLBCL

Matthew S. McKinney, MD, discusses the tolerability observed in the LOTIS-2 trial of loncastuximab tesirine of patients with relapsed/refractory diffuse large B-cell lymphoma.

Part 2: Selecting a Non-CAR T-Cell Treatment in Third-Line R/R DLBCL

During a live virtual event, Jason Westin, MD, discussed with participants the choice of third-line treatment for relapsed/refractory diffuse large B-cell lymphoma for a patient who declines chimeric antigen receptor T-cell therapy.

Part 1: Real-World Barriers to CAR T-Cell Therapy in Advanced DLBCL

During a live virtual event, Jason Westin, MD, discussed the challenges of giving patients access to chimeric antigen receptor T-cell therapy.

Part 2: LOTIS-2 Trial Includes High-Risk Patients and CAR T Sequencing in R/R DLBCL

During a live virtual event, Philippe Armand, MD, PhD, discussed the results of the LOTIS-2 trial of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

Part 1: Tafasitamab/Lenalidomide Shows Durable Responses in R/R DLBCL

During a live virtual event, Philippe Armand, MD, PhD, discussed the results of the outcomes of clinical trials of tafasitamab plus lenalidomide as well as loncastuximab tesirine in diffuse large B-cell lymphoma.

Part 2: Sequencing Loncastuximab and CAR T-Cell Therapy in DLBCL

During a live virtual event, Ann S. LaCasce, MD, MMSC, discussed sequencing and using loncastuximab tesirine as a therapy for patients with diffuse large B-cell lymphoma.

Part 1: Selecting Third-Line Options for DLBCL With CAR T-Cell Therapy

During a live virtual event, Ann LaCasce, MD, MMSc, discusses third-line treatment options for diffuse large B-cell lymphoma when considering eligibility for chimeric antigen receptor T-cell therapy.

Part 3: Barriers to Loncastuximab Before CAR T-Cell Therapy in DLBCL

During a live virtual event, Paolo Caimi, MD, discussed the barriers to using loncastuximab tesirine for diffuse large B-cell lymphoma preceding chimeric antigen receptor T-cell therapy.

Part 2: Loncastuximab as a Third-Line Therapy for Relapsed/Refractory DLBCL

During a live virtual event, Paolo Caimi, MD, discussed the toxicity and dosage of loncastuximab tesirine as a third-line therapy for diffuse large B-cell lymphoma before receiving chimeric antigen receptor T-cell therapy.

Part 1: Choosing a Third-Line Treatment for Refractory DLBCL

During a live virtual event, Paolo Caimi, MD, discussed third-line treatment of a patient with diffuse large B-cell lymphoma and navigating obstacles to treatment.

Part 3: Third-Line Use of Loncastuximab for Relapsed/Refractory DLBCL

During a live virtual event, Beth A. Christian, MD, discussed data on third-line loncastuximab tesirine treatment in patients with diffuse large B-cell lymphoma and how to sequence treatments for patients who may receive CAR T-cell therapy.

Part 2: Real-World Challenges with CAR T-Cell Therapy in DLBCL

During a live virtual event, Beth A. Christian, MD, discussed real-world challenges of providing timely access to CAR-T cell therapy for patients with diffuse large B-cell lymphoma.

Part 1: Decision-Making for Third-Line Treatment of Transplant-Ineligible DLBCL

During a live virtual event, Beth A. Christian, MD, discussed approaches to third-line treatment of transplant-ineligible DLBCL and when to consider CAR T-cell therapy.

Part 3: Kline Discusses the Use of Tafasitamab in Certain Patients with R/R DLBCL

While antibody-drug conjugates have shown promise in patients with relapsed/refractory diffuse large B-cell lymphoma, there are other options that can help patients before moving on to CAR T-cell therapy.

Part 2: Loncastuximab Provides Potential Bridge Therapy for R/R DLBCL

Justin Kline, MD, discusses what makes loncastuximab tesirine-lpyl a good bridge therapy for patients with relapsed/refractory diffuse large B-cell lymphoma to potential CAR T-cell therapy.

Part 1: Kline Discusses Challenges of CAR T-Cell Therapy in R/R DLBCL

Looking at the challenges with CAR T-cell therapies in patients with diffuse large B-cell lymphoma Justin Kline, MD, discusses the best available therapies for patients who relapse on treatment.

Part 3: Polatuzumab Vedotin Plus Bendamustine and Rituximab Shows Promise in Patients With DLBCL

The efficacy and data for the combination of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma show effective outcomes for patients that clinicians can use when discussing treatment options.

Part 2: Shah Discusses Challenges in Using Lenalidomide Plus Tafasitamab for Patients With DLBCL

Looking at the combination of lenalidomide plus tafasitamab for patients with diffuse large B-cell lymphoma shows promise for patients' treatment, but challenges remain that clinicians need to address.

Part 1: Treatment Options and Relevant Data for Patients With DLBCL

During a live virtual event with other physicians, Bijal Shah, MD, MS, discussed treatment options for patients with diffuse large B-cell lymphoma and the data that backs up the efficacy for these options.